Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16818649 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Li YY, et al. (2006) Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 66, 6741-7 16818649
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S75-p - BAD (human)
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), PANC-1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  PCI-55 cell line
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Pim3 (human) co-immunoprecipitation, transfection of wild-type enzyme, phospho-antibody, microscopy-colocalization, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Pim3 (human) decrease
Pim3 (human) increase

S99-p - BAD (human)
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), PANC-1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  PCI-55 cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Pim3 (human) no change compared to control
Pim3 (human) no change compared to control

S118-p - BAD (human)
Orthologous residues
BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), PANC-1 (pancreatic)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  PCI-55 cell line
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA Pim3 (human) no change compared to control
Pim3 (human) no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.